

Terapia precoce anti-COVID sul territorio


Dr. Simone Vasilij Benatti

Malattie Infettive

ASST- Papa Giovanni XXIII – Bergamo

sbenatti@asst-pg23.it

teleinfe@asst-pg23.it





Nirmatrelvir/ritonavir

Nirmatrelvir è un INIBITORE della
PROTEASI di SARS-CoV-2

Ritonavir (RTV) è solo booster

POSOLOGIA:

2 + 1 capsule (intere)

[1 + 1 se EGFR tra 30 e 60]

Con o senza cibo

Ogni 12 h

Per 5 gg


Poi STOP!

Entro quanto tempo?

- Max 5 gg dall'esordio dei sintomi
- Prima si fa, meglio è
- Solo se appartiene a categoria a rischio
- Il test molecolare non è richiesto

L'importante è che il paziente:

- ✓ Non sia da ricoverare (non deve avere necessità di O₂ – se già in LTOT, non deve essere aumentato...)
- ✓ Non sia una donna in gravidanza (attenzione con contraccettivi orali, evitare gravidanza fino a 7 gg dopo la fine della cura)
- ✓ Abbia EGFR > 30 mL/min



The major phases and suggested time points that are critical in COVID-19. The **Pre-exposure period**, the **Incubation period** starting at T_E (Time of exposure), the **Detectable Viral Replication Phase** T_{VR} (Time of viral replication), the **Viral Symptom Phase** T_S (Time of symptom onset), the **Early Inflammatory Phase** T_{EI} (Time of early inflammation), the **Secondary Infection Phase** starts at T_{SI} (Time of secondary infection) the **Hyperinflammatory Phase** which starts at T_{HI} (Time of Hyperinflammation onset) and the **Tail Phase** that starts at T_T (Time of the tail onset)

A chi si può dare?

Tabella-1 - CRITERI ELEGGIBILITA' AIFA (gen/2022)					
		Sotrovimab	Remdesivir precoce	Molnupiravir	Nirmatrelvir
Timing	esordio sintomi	≤ 7 gg	≤ 7 gg	≤ 5 gg	≤ 5 gg
Criteri di esclus.	età minima	≥ 12	≥ 18	≥ 18	≥ 12
	peso minimo	> 40 Kg	> 40 Kg	> 40 Kg	> 40 Kg
	gravidanza	No	No	No [®]	No ^{&}
	allattamento	No?	No (stop temporaneamente)		
	EGFR < 30	Sì	No	No	No (se EGFR 30-60: ridurre dose)
	ALT > N	Sì	Solo se < 5 ULN	No	Non se Child C
Efficacia in soggetti non vaccinati		85% ^a	87% ^b	31% ^c	88% ^d
Criteri di inclus.	età > 65	Sì	No		
	BMI ≥ 30	Sì	Sì		
	Diabete	Non controllato o con compl. croniche	Non controllato		
	Patol. Cardiovasc.	Sì	Solo se grave (SCC, CAD, CMD)		
	Patol. Cerebrovasc.	Sì	No		
	Immunodeficienza	Sì	Sì		
	Patol. Polmonare	Sì	Solo se grave		
	Epatopatia	Sì	No		
	Hb-patie	Sì	No		
	Patol. del neurosviluppo o neurodegener.	Sì	No		
	Neoplasia oncologica/ematol. in fase attiva	Sì	Sì		
	IRC	Sì	Sì (ma EGFR < 30 è criterio di esclusione)		

Effetti collaterali

- Di tipo digestivo
- Diarrea

(Solitamente non rilevanti)


Formula di Cockcroft-Gault per EGFR

$$eCrCl = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{72 \times \text{Creatinine}_{\text{serum (mg/dL)}}} \times 0.85 \text{ if female}$$

Oppure....

Scaricare una App, tipo MedCalc

Stadi insufficienza renale



Interazioni farmacologiche

 COVID-19 Drug Interactions

 UNIVERSITY OF
LIVERPOOL

[About Us](#)[Interaction Checkers](#)[Prescribing Resources](#)[Contact Us](#)

New COVID therapy - interactions with **molnupiravir** now available

Interaction Checker

Access our free, comprehensive and user-friendly drug interaction charts

Prescribing Resources

Printable interaction tables, interaction summary charts and clinical prescribing resources

Twitter

 @covidDDIs

Follow us on Twitter for interaction news and for the latest additions and changes to the website

Interazioni farmacologiche

If a drug is not listed below it cannot automatically be assumed it is safe to coadminister.

COVID Drugs	Co-medications	Drug Interactions
nirmatre	amlodip	☒ Check COVID/COVID drug interactions
		Reset Checker
☒ A-Z ☐ Class ☐ Trade	☒ A-Z ☐ Class	Switch to table view Results Key
☒ Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.] ⓘ	☒ Amlodipine ⓘ	Potential Interaction
	☒ Amlodipine ⓘ	Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.]
☒ Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.] ⓘ		Amlodipine

Interazioni farmacologiche

Potential Interaction

Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.]

Amlodipine

Quality of Evidence: Very Low ⓘ

Summary:

Coadministration has not been studied. Amlodipine is metabolized by CYP3A4. Nirmatrelvir/ritonavir is predicted to increase amlodipine exposure by ~2-fold based on drug-drug interactions studies with amlodipine and indinavir/ritonavir or paritaprevir/ritonavir leading to the recommendation to reduce amlodipine dosage by 50%. However, a dose adjustment can be optional in the case of amlodipine given that patients can be advised to monitor for symptoms of hypotension and to temporarily pause the antihypertensive drug if needed. The inhibitory effect of ritonavir is expected to last up to 3 days after the last administered dose of nirmatrelvir/ritonavir.

Description:

Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of calcium channel antagonists. Careful monitoring of therapeutic and adverse effects is recommended when this medicine is concomitantly administered with ritonavir.

Paxlovid Summary of Product Characteristics, Pfizer Ltd, February 2022.

Co-administration may increase concentrations of the calcium channel

Attenzione con:

- Anticoagulanti orali (warfarin, DOAC...) → Sospendere? Passare a Clexane?
- Ca++ antagonisti → Sospendere/ridurre?
- Alfa-litici → Sospendere?
- Statine → Sospendere!
- Salmeterolo → Salbutamolo?
- Antirigetto → Valutare alternative

☒ A-Z ☐ Class ☐ Trade		☒ A-Z ☐ Class		Switch to table view	Results Key
☒ Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.]	i	☒ Salbutamol (Albuterol)	i	Do Not Coadminister Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.]	
		☒ Salmeterol	i	Salmeterol More Info ▾	
☒ Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.]	i	☒ Salmeterol	i	No Interaction Expected Nirmatrelvir/ritonavir (5 days) [Please read the interaction details as management of these interactions may be complex.] Salbutamol (Albuterol)	

Per ogni dubbio o per casi particolari...

- Tel. 339-8756575
- LUN > VEN – h 9.00 > 16.00

Oppure:

- teleinfe@asst-pg23.it

Grazie.